Obesity and type 2 diabetes are among the cardiometabolic diseases included in Novo Nordisk’s R&D pact with Replicate Biosciences, a deal that could pay out up to $550 million. Startup Replicate specializes in therapies and vaccines based on self-replicating RNA.
The post Novo Nordisk Turns to Self-Replicating RNA Startup to Discover New Metabolic Medicines appeared first on MedCity News.
